NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Antares Pharma, Inc. (“Antares Pharma”) (NASDAQ:ATRS) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/ATRS-Info-Request-Form-1719. There is no cost or obligation to you.
Antares Pharma received a letter from the U.S. Food and Drug Administration on October 11, 2017 stating that the agency had “identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments” for its product candidate Xyosted.
Then on October 20, 2017, Antares announced receipt of a Complete Response Letter from the FDA regarding the New Drug Application for Xyosted. The Company stated that the FDA could not approve the NDA in its present form due to concerns that Xyosted “could cause a clinically meaningful increase in blood pressure” and also noted the FDA’s concerns “regarding the occurrence of depression and suicidality.”
To learn more about the investigation of Antares Pharma contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/ATRS-Info-Request-Form-1719.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.